THU0218 the Efficacy and Drug Survival of the Biosimilar Infliximab (CT-P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results From the Turkbio Registry

doi 10.1136/annrheumdis-2018-eular.6440
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy